Davis Polk & Wardwell represented Roivant Sciences, while Latham & Watkins represented the underwriters in the offering. Roivant Sciences (Nasdaq: ROIV) has announced its $230 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Pacific Biosciences of California on the offering, and Davis Polk advised the representatives of the several underwriters involved. Pacific Biosciences of California Inc. announced...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Deciphera Pharmaceuticals, and Davis Polk advised the joint book-running managers involved in the offering. Deciphera Pharmaceuticals Inc. announced a $135.1 million SEC-registered common stock...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Terns Pharmaceuticals in the offering and Davis Polk advised the underwriters involved. Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
You must be a Standard 1 Year member to access this content.
White & Case advised Ormat Technologies, Davis Polk advised the joint book-running managers and representatives of the several underwriters in the offering. Kirkland advised ORIX Corporation....
You must be a Standard 1 Year member to access this content.
Cooley represented Zoetis, while Davis Polk advised the joint book-running managers in the offering. Zoetis Inc. executed its offering of $600 million aggregate principal amount of its...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented NextGen Healthcare, while Davis Polk advised J.P. Morgan Securities LLC, the representative of the initial purchasers in the offering. NextGen Healthcare, Inc....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the deal, while Davis Polk advised the representatives of the several underwriters. Denali Therapeutics, a biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the placement agent, BofA Securities, Inc., in the offering. Solid Biosciences, Inc. executed its private placement of $75 million of common stock. The financing is...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the representative of the underwriters in the offering. Gamida Cell Ltd. announced the $20 million SEC-registered follow-on offering of 12,905,000 ordinary shares. The ordinary shares...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the representatives of the underwriters in the offering. Allakos Inc. announced its offering of 29,882,000 shares of common stock, for total gross proceeds of...
You must be a Standard 1 Year member to access this content.
